When it comes to AI adoption in law, the stakes are rarely just about speed or automation — they’re about trust. Confidentiality is sacrosanct, and yet the allure of AI-driven productivity looms large. Into this paradox steps Syntracts, a Washington, D.C.-based startup that’s quietly building what it believes is the missing link: a secure, on-premises…
Water leaks are among the most persistent, least visible failures of modern infrastructure — and one of the most expensive. Every year, nearly a third of the world’s treated drinking water disappears before it ever reaches a tap. The reasons are rarely dramatic: ageing pipes, poor maintenance, lack of monitoring. Yet the outcomes are costly…
California-based Graph AI, a promising new entrant in the pharmacovigilance space, has raised $3 million in a seed funding round led by Bessemer Venture Partners. Founded in 2024, Graph AI is pioneering an AI-native platform designed to transform the cumbersome and error-prone process of adverse drug event (ADE) monitoring that pharmaceutical companies are mandated to…
In a crowded biotech landscape where antibiotic breakthroughs rarely break through, Peptilogics has secured a commanding $78 million in an oversubscribed Series B2 round to fuel its pivotal trial of zaloganan (PLG0206), a therapeutic candidate aimed at prosthetic joint infections (PJI). The financing was led by Presight Capital, Thiel Bio, and Founders Fund, with fresh capital from…
In a move that could reshape how software companies scale, SaaS Capital has closed a $100 million Fund V to extend its growth debt model into subscription AI applications. Rather than diluting ownership, the firm is betting on debt structures—tailored for recurring-revenue businesses—to back this emerging frontier. Debt, Not Dilution: The Logic Behind Fund V…
In an era when hospitals feel perpetually stretched, Brook.ai has quietly begun to reimagine what “care” means. The Seattle‑based healthtech startup, which melds artificial intelligence with human clinical teams, has just raised $28 million in a Series B round co‑led by UMass Memorial Health and Morningside, setting the stage for broader deployment across U.S. health…
In the evolving landscape of sales and customer service, where artificial intelligence increasingly reshapes human interactions, one startup is gaining decisive momentum. Second Nature, a dynamic AI-powered training platform, has secured $22 million in a Series B funding round, signaling strong investor confidence in its vision to revolutionize how sales and service teams prepare for…
As enterprises rush to harness the transformative potential of private LTE and 5G networks, complexity threatens to stall adoption. OneLayer, a Boston-based startup helmed by CEO and co-founder Dave Mor, is staking its claim as the essential infrastructure enabler that bridges cellular technology and enterprise IT. Closing a $28 million Series A round led by…
The insurance industry faces an unprecedented reckoning as climate change drives up the frequency and severity of natural disasters. Stand, a San Francisco-based startup, is taking a data-driven, mitigation-first approach to insuring homes exposed to catastrophic risks like wildfire, flood, and wind. Having underwritten over $1 billion in insured value in wildfire-prone California within a…
BridGene Biosciences, a San Jose–based biotech innovator focused on tackling traditionally “undruggable” molecular targets, has raised $28 million in a Series B+ funding round led by Bayland Capital. This capital injection will accelerate clinical advancement of BridGene’s lead candidate, BGC-515—a covalent TEAD inhibitor aimed at solid tumors—and fuel expansion of its proprietary IMTAC™ chemoproteomic platform…
